Myricitrin is a natural occurring flavonoid glycoside that possesses effects on inhibiting nitric oxide (NO) transmission and preventing inflammatory reaction. Although previous study showed the myricitrin possesses antibone loss effects via reducing the expression of IL-6 and partially suppressing reactive oxygen species (ROS) production. However, the effects of myricitrin on nuclear factor-kappaB ligand (RANKL)-stimulated osteoclastogenesis have not yet been further investigated. The current study was aimed to demonstrating the inhibitory effects of myricitrin on RANKL-stimulated osteoclastogenesis and relevant mechanisms. We found myricitrin significantly suppressed osteoclastogenesis suggesting that it may acts on RANKL/ RANK induced downstream signal cross cascading in osteoclast precursors. In that, our Western blotting results showed myricitrin significantly attenuated RNAKL/ MAPKs (phosphorylation of p38, ERK, JNK) and AKT signal cascading. Complementing previous study, our results suggesting as a natural inhibitor, myricitrin possesses the potential therapeutic effects on inflammatory osteolysis.
reported myricitrin possesses effective antioxidative, 11 anti-inflammatory 12 and can protect a variety of cells from in vitro and in vivo injuries. 13, 14 Otherwise, recently studies have showed myricitrin regulates various cellular signalling cascades including STAT3 15 and PI3K/Akt/eNOS. 16 Moreover, myricitrin demonstrated suppression effects on myocardial apoptosis relied on the ERK/p53-mediated mitochondrial apoptosis pathway. 17 Furthermore, the most recently study showed the protective effects of myricitrin against osteoporosis via reducing the expression of IL-6 and partially suppressing ROS production. 18 Nevertheless, as dairy natural occurring inhibitor, deeply exploring the novel effects of myricitrin on osteoclastogenesis still on the way. In our current study, we aimed to demonstrate the cellular effects of myricitrin on osteoclastogenesis and precise mechanisms underlying. 
| MATERIALS AND METHODS

| Reagents and antibodies
Myricitrin
| OCs differentiation
All animal care and experimental protocols were approved by the 16, 19, 20 Briefly, by flushing the femurs and tibiae of 5-week-old ICR mice with a-minimum essential medium and suspended in a-MEM supplemented with 10% foetal bovine serum. Nonadherent cells were collected and cultured for 3 days in the presence of M-CSF (20 ng/mL).
Floating cells were discarded, and adherent cells on dish bottoms were classified as BMMs. BMMs were seeded at 3. 
| Cell viability assays and cell apoptosis assay
Cell viability and apoptosis of BMMs after myricitrin (0, 0.5, 5 or 20 lmol/L/mL) treatments was studied by XTT (Indianapolis, IN, USA) and flow cytometry as previous studies reported, 
| Bone absorption assay and confocalmicroscopy immunofluorescence
Bone absorption assay and filamentous actin immunofluorescence staining method were following previously described. 22 Briefly, BMMs were seeded onto bovine bone slices with three replicates. 
| RT-PCR
Total RNA was isolated with QIAzol reagent (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions RNA (1 lg) was reverse transcribed using oligo dT primers (10 lg) and dNTPs of an initial denaturation step at 95°C for 5 minutes followed by 40 cycles of denaturation at 95°C for 1 minute, annealing at 60°C for 30 seconds and extension at 72°C for 1 minute. The specificity of the SYBR green assays was confirmed by melting-point analysis.
Expression data were calculated from the cycle threshold (Ct) value using the Ct. Primers employed for amplification are shown in Table 1 .
| Western blotting
Protein lysates from myricitrin treated cells were prepared in a buffer containing 50 mmol/L with 50 lg/mL phenylmethylsulfonyl fluoride (Thermo Scientific, Waltham, MA, USA). Thirty micrograms of total cell proteins was mixed with loading buffer and separated on 10% SDS-PAGE gels, and the proteins in the gels were electro-trans- 
| Statistical analysis
Experiments were conducted separately at least 3 times, and all data are presented as the mean AE standard deviation (SD). All data analysis was performed using SPSS software package ver. 14.0 (SPSS, Chicago, IL); one-way ANOVA was used for comparison among the different groups. Post hoc testing of differences between groups was performed by using Duncan's test when the ANOVA was significant. All results were considered to be significant at the 5% critical level (P < .05).
| RESULTS
| Myricitrin inhibits TRAP-positive cells differentiation
Our cellular culture results showed, following M-CSF plus RANKL treatment, myricitrin significantly decreased the TRAP-positive multi nucleated OCs formation in the dose-dependent manner ( Figure 1B ).
Otherwise, we performed XTT assay and flow cytometry to investigate the cytotoxicity and cellular apoptosis, respectively. Both 
| DISCUSSION
Osteoporosis commonly caused by enhanced pathological bone resorption or bone loss because of the increased OCs activation. 24 Previous study proved excessive OCs differentiation (osteoclastogenesis) is mostly via the classic signalling pathway: RANKL, which has been a potential valuable target for treating osteoporosis. 5 Our current study of myricitrin down-regulation effects on osteoclastogenesis and decreased mature OC's bone resorptive function have demonstrated F I G U R E 2 Myricitrin inhibited osteoclast bone resorption and F-actin ring structure. A, Representative scanning electron microscopy images of F-actin ring structure and bone resorption pits; B, Number of F-actin ring and bone resorption pits. All experiments were performed at least three times, and the significance was determined as indicated in methods (*P < .05) myricitrin as a natural inhibitor, possessing therapeutic potential on treating pathological bone loss disease. Moreover, complementary to previous study, we further investigated the effects of myricitrin on cfos/NFATc1 and its upstreaming signalling cascades such as MAPKs and AKT, during osteoclastogenesis.
During the past decade, most large pharmaceutical companies ceased natural products (compounds/agents/inhibitors) screening, which is initial step for drug discovery. 25, 26 Despite the lack of effort by most of the large pharmaceutical companies, natural product research has still been active during the past decade. 27, 28 Institutions mainly from China, Korea, India, Japan and United States keep engaging in the work of natural products study, for re-establish natural products as a major source for potential drug discovery. 19, 26, [29] [30] [31] Given that only limited biological properties or functional activities have been worked out for each natural product, there still has a "long way to go" for fully identifying the biological activities of natural products. 33, 34 Myricitrin is a naturally occurring flavonoid derived from bayberry bark and fruit, which has been reported to exhibit numerous biological activities such as antioxidative, anti-inflammatory and antinociceptive effects. 12, 14, 35 Despite the biological activities, myricitrin is relatively easy to extract and purify. 15 Documents studies showed myricitrin regulates several extracellular signalling pathways, such as STAT3, PI3K/Akt/eNOS 15 and ERK/p53 17 The most recently study showed myricitrin inhibited osteoporosis of ovariectomized rats, which was associated with reducing the expression of IL-6 and partially suppressing ROS production. 18 In complementary to these findings, we performed F-actin ring formation and bone absorption assay in vitro to explore the inhibitory effects of myricitrin on osteoclast differentiation and further investigate the underlying mechanisms involved in these down-regulation effects. Our results showed both impaired F-actin ring formation and enlarged bone resorption pits were dramatically decreased by myricitrin which consistently with our previous in vitro study.
RANKL interacts to its receptor RANK is a pivotal upstreaming signal pathway involved in osteoclastogenesis, further triggers various downstreaming signalling cascades, such as MAPKs (p-38, ERK and JNK) and Akt, which leading to stimulate the activation of critical genes for osteoclastogenesis. 7, 36 In addition, paralleling RANKL/RANK signalling, ROS directly affect osteoclastogenesis by increasing TNF-a and IL-6, which in turn indirectly up regulates RANKL expression. 37 Previously, Huang et al 18 In that, as previous study reported, phosphorylation-ERK is the crucial regulator of AP-1 (c-Fos and c-JUN) activation in BMMs. 38 Phosphorylation of c-Fos is sustained by ERK signalling, impaired ERK activation will indirectly leading the attenuation of c-Fos. 39 p38
is particularly critical for the OCs early stage differentiation, as it promotes the activity of microphthalmia-associated transcription factor (MITF) and TRAP expression. 6 AKT signalling is crucial in OCs survival. 40 Previous studies showed the importance of the AKT/ NFATc1 signalling cascades in OCs differentiation. 41 Therefore, combined with the results of our Western blot results, we speculate MAPKs and AKT cascades might be an underlying mechanisms involved in the regulation of myricitrin on osteoclastogenesis. However, PI3K and STAT3 are two up signal transduction activators of AKT during advanced cell survival stage. 42 Thus, further investigations of myricitrin on PI3K and STAT3 effects during OC differentiation should necessarily be conducted.
In sum, our current study demonstrated the inhibitory effects of myricitrin on osteoclastogenesis in vitro and therapeutic effects in pathological osteoporosis in vivo, respectively. Moreover, our study explored myricitrin consequently attenuates the activation of the OCs-specific transcription factors c-Fos/NFATc1. Further, we identified that myricitrin functioned by attenuating the RANKL/ MAPKs signalling pathway cross-talking RANKL/AKT signalling cascades. Combined with previous studies, our current results indicate myricitrin are promising candidates for the treatment of pathological bone loss diseases.
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